EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.
These guidelines summarize the current views of the European Association of Nuclear Medicine Neuroimaging Committee (ENC). The purpose of the guidelines is to assist nuclear medicine practitioners when making recommendations, performing, interpreting, and reporting the results of brain perfusion single photon emission computed tomography (SPECT) studies using (99m)Tc-labelled radiopharmaceuticals. The aim is to achieve a high quality standard for brain perfusion SPECT imaging, which will increase the diagnostic impact of this technique in clinical practice. The present document replaces a former version of the guideline published in 2001 which was inspired by the Society of Nuclear Medicine Procedure Guideline for Brain Perfusion SPECT [1], the views of the Society of Nuclear Medicine Brain Imaging Council [2], and the individual experience of experts in European countries. The guidelines are intended to present information specifically adapted to European practice. The information provided should be taken in the context of local conditions and regulations.
Kapucu
Ozlem L
OL
Department of Nuclear Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey. ozlemkapucu@gmail.com
Nobili
Flavio
F
Varrone
Andrea
A
Booij
Jan
J
Vander Borght
Thierry
T
Någren
Kjell
K
Darcourt
Jacques
J
Tatsch
Klaus
K
Van Laere
Koen J
KJ
D000328:Adult; D001921:Brain / Q000000981:diagnostic imaging*; D002648:Child; D000075202:Contraindications; D005060:Europe; D005260:Female; D006801:Humans; D007090:Image Interpretation, Computer-Assisted; D009683:Nuclear Medicine / Q000295:instrumentation / Q000379:methods*; D015609:Organotechnetium Compounds; D010346:Patient Care Management; D055420:Perfusion Imaging / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D011247:Pregnancy; D019275:Radiopharmaceuticals / Q000009:adverse effects; D058028:Research Report; D012952:Societies; D015899:Tomography, Emission-Computed, Single-Photon / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*
D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals